![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DC Argentieri, DM Ritchie, MP Ferro, T Kirchner, MP Wachter, DW Anderson, ME Rosenthale and RJ Capetola
Research Laboratories, R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey.
Tepoxalin [5-(4-chlorophenyl)-N-hydroxy-(4-methoxyphenyl)-N-methyl-1H- pyrazole-3-propanamide] is a potent inhibitor of sheep seminal vesicle cyclooxygenase (CO) (IC50 = 4.6 microM), rat basophilic leukemia cell (RBL-1) lysate CO (IC50 = 2.85 microM) and CO from intact RBL-1 cells (IC50 = 4.2 microM). The compound inhibits the production of thromboxane B2 (TxB2) in Ca++ ionophore A-23187-stimulated human peripheral blood leukocytes (HPBL; IC50 = 0.01 microM) and human whole blood (IC50 = 0.08 microM) and is a potent inhibitor of epinephrine- induced human platelet aggregation (IC50 = 0.045 microM). Tepoxalin inhibits lipoxygenase (LO) in RBL-1 lysates (IC50 = 0.15 microM) and intact RBL-1 cells (IC50 = 1.7 microM) and inhibits the generation of leukotriene B4 (LTB4) in calcium ionophore A-23187-stimulated HPBL (IC50 = 0.07 microM) and human whole blood (IC50 = 1.57 microM). Human platelet 12-LO (IC50 = 3.0 microM) is inhibited, but 15-LO is only weakly so (IC50 = 157 microM). In vivo, tepoxalin, administered orally, demonstrated potent anti-inflammatory activity in the established adjuvant arthritic rat (ED50 = 3.5 mg/kg) and potent analgesic activity in the acetic acid abdominal construction assay in mice (ED50 = 0.45 mg/kg). In an ex vivo whole blood eicosanoid production assay, tepoxalin produces a dose-related inhibition of prostaglandin (PG) and LT production in dogs (PGF2 alpha - ED50 = 0.015 mg/kg; LTB4 - ED50 = 2.37 mg/kg) and adjuvant arthritic rats following oral administration. In adjuvant arthritic rats, tepoxalin is devoid of ulcerogenic activity within its anti-inflammatory therapeutic range (1-33 mg/kg p.o.) and does not exhibit ulcerogenic activity in normal rats at doses lower than 100 mg/kg (UD50 = 173 mg/kg p.o.). Tepoxalin represents a new class of anti-inflammatory drugs which may exhibit less gastrointestinal toxicity and may be efficacious in immunoinflammatory disease states where excessive PG and LT production has been implicated and may offer a significant alternative to nonsteroidal and corticosteroidal anti-inflammatory therapy.
This article has been cited by other articles:
|
|
 |
|
  S. L. Curry, S. M. Cogar, and J. L. Cook Nonsteroidal Antiinflammatory Drugs: A Review J. Am. Anim. Hosp. Assoc., September 1, 2005; 41(5): 298 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen, D. B. Jump, M. B. Grant, W. J. Esselman, and J. V. Busik Dyslipidemia, but Not Hyperglycemia, Induces Inflammatory Adhesion Molecules in Human Retinal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 5016 - 5022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhu, M. Medhora, W. B. Campbell, N. Spitzbarth, J. E. Baker, and E. R. Jacobs Chronic Hypoxia Activates Lung 15-Lipoxygenase, Which Catalyzes Production of 15-HETE and Enhances Constriction in Neonatal Rabbit Pulmonary Arteries Circ. Res., May 16, 2003; 92(9): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Klegeris and P. L. McGeer Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP J. Leukoc. Biol., March 1, 2003; 73(3): 369 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rioux and A. Castonguay The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-{kappa}B Carcinogenesis, September 1, 2000; 21(9): 1745 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kirchner, D. C. Argentieri, A. G. Barbone, M. Singer, M. Steber, J. Ansell, S. A. Beers, M. P. Wachter, W. Wu, E. Malloy, et al. Evaluation of the Antiinflammatory Activity of a Dual Cyclooxygenase-2 Selective/5-Lipoxygenase Inhibitor, RWJ 63556, in a Canine Model of Inflammation J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 1094 - 1101. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. S. C. Tam, D. H. S. Lee, E. Y. Wang, D. G. Munroe, and C. Y. Lau Tepoxalin, a Novel Dual Inhibitor of the Prostaglandin-H Synthase Cyclooxygenase and Peroxidase Activities J. Biol. Chem., June 9, 1995; 270(23): 13948 - 13955. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
